{"schema_version":"secwatch.filing_event.v1","accession":"0001759425-24-000037","form_type":"8-K","ticker":"MIRM","cik":"0001759425","company_name":"Mirum Pharmaceuticals, Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.501168+00:00","generated_at":"2026-05-30T02:04:33.871484+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Mirum Q3 net product sales $90.3M (+89% YoY); raises FY 2024 guidance to $330-335M","bullets":["LIVMARLI net sales $59.1M; CHOLBAM/CHENODAL combined $31.2M.","Cash & investments $293.8M vs $286.3M at Dec 2023; OpEx $103.1M incl $18M non-cash.","PDUFA date for chenodiol in CTX set for Dec 28, 2024.","Volixibat granted breakthrough therapy designation for PBC; interim data at AASLD.","In-licensed PDE4D inhibitor MRM-3379 for Fragile X syndrome; Phase 2 expected in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001759425-24-000037","json":"https://secwatch.observer/filing/0001759425-24-000037.json","markdown":"https://secwatch.observer/filing/0001759425-24-000037.md","text":"https://secwatch.observer/filing/0001759425-24-000037.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1759425/000175942524000037/0001759425-24-000037-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1759425/000175942524000037/mirm-20241112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:04:33.871484+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}